Active ingredient: Carvedilol Phosphate

Form/Route: Extended Release Capsules/Oral

Recommended studies: 3 studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in-vivo
   Strength: 40 mg
   Subjects: Healthy males and nonpregnant females, general population.
   Additional Comments:

2. Type of study: Fed
   Design: Single-dose, two-way crossover in-vivo
   Strength: 40 mg
   Subjects: Healthy males and nonpregnant females, general population.
   Additional Comments:

3. Type of study: Sprinkle
   Design: Single-dose, two-way crossover in-vivo
   Strength: 40 mg
   Subjects: Healthy males and nonpregnant females, general population.
   Additional Comments:

Analytes to measure (in appropriate biological fluid): Carvedilol (the racemate of parent drug) and 4-hydroxyphenyl-carvedilol (active metabolite) in plasma.

Bioequivalence based on (90% CI): Carvedilol (racemate)

Please submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and Cmax.

Waiver request of in-vivo testing: 10, 20, and 80 mg based on (i) acceptable bioequivalence studies on the 40 mg strength, (ii) proportionally similar across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.
Dissolution test method and sampling times:

Please note that a Dissolution Method Database is available to the public at the OGD website at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

In addition to the method above, for modified release products, dissolution profiles on 12 dosage units each of test and reference products generated using USP Apparatus I at 100 rpm and/or Apparatus II at 50 rpm in at least three dissolution media (pH 1.2, 4.5 and 6.8 buffer) should be submitted in the application. Agitation speeds may have to be increased if appropriate. It is acceptable to add a small amount of surfactant, if necessary. Please include early sampling times of 1, 2, and 4 hours and continue every 2 hours until at least 80% of the drug is released, to provide assurance against premature release of drug (dose dumping) from the formulation. Specifications will be determined upon review of the data submitted in the application.

Due to concerns of dose dumping from this drug product when taken with alcohol, please conduct additional dissolution testing using various concentrations of ethanol in the dissolution medium, as follows:

Testing Conditions: 900 mL, 0.1 N HCl, apparatus 1 (basket) @ 75 rpm, with and without the alcohol (see below):

Test 1: 12 units tested according to the proposed method (with 0.1 N HCl), with data collected every 15 minutes for a total of 2 hours.

Test 2: 12 units analyzed by substituting 5% (v/v) of test medium with Alcohol USP, and data collection every 15 minutes for a total of 2 hours.

Test 3: 12 units analyzed by substituting 20% (v/v) of test medium with Alcohol USP, and data collection every 15 minutes for a total of 2 hours.

Test 4: 12 units analyzed by substituting 40% (v/v) of test medium with Alcohol USP, and data collection every 15 minutes for a total of 2 hours.

Both test and RLD products must be tested accordingly and data must be provided on individual unit, means, range and %CV on both strengths.